These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20810399)
21. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348 [TBL] [Abstract][Full Text] [Related]
22. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lourdudoss C; Vollenhoven Rv Lupus; 2014 Mar; 23(3):299-304. PubMed ID: 24399811 [TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Kasitanon N; Petri M; Haas M; Magder LS; Fine DM Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682 [TBL] [Abstract][Full Text] [Related]
24. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125 [TBL] [Abstract][Full Text] [Related]
27. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. Hara R; Miyazawa H; Nishimura K; Momoi T; Nozawa T; Kikuchi M; Sakurai N; Kizawa T; Shimamura S; Yasuda S; Hiromura K; Sada KE; Kawaguchi Y; Tamura N; Takei S; Takasaki Y; Atsumi T; Mori M Mod Rheumatol; 2015; 25(6):858-64. PubMed ID: 26215483 [TBL] [Abstract][Full Text] [Related]
28. Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J J Clin Pharm Ther; 2012 Apr; 37(2):217-20. PubMed ID: 21517926 [TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Wilson EC; Jayne DR; Dellow E; Fordham RJ Rheumatology (Oxford); 2007 Jul; 46(7):1096-101. PubMed ID: 17409128 [TBL] [Abstract][Full Text] [Related]
31. [Interest of mycophenolate mofetil in children with membranous lupus nephritis]. Gargah T; Goucha-Louzir R; Lakhoua MR Nephrol Ther; 2010 Dec; 6(7):564-8. PubMed ID: 20829140 [TBL] [Abstract][Full Text] [Related]
32. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Aragon E; Chan YH; Ng KH; Lau YW; Tan PH; Yap HK Lupus; 2010 Jul; 19(8):965-73. PubMed ID: 20581019 [TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Nannini C; Crowson CS; Matteson EL; Moder KG Lupus; 2009 Apr; 18(5):394-9. PubMed ID: 19318390 [TBL] [Abstract][Full Text] [Related]
34. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L Lupus; 2007; 16(9):707-12. PubMed ID: 17728363 [TBL] [Abstract][Full Text] [Related]
35. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Karim MY; Pisoni CN; Ferro L; Tungekar MF; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR Rheumatology (Oxford); 2005 Oct; 44(10):1317-21. PubMed ID: 16049051 [TBL] [Abstract][Full Text] [Related]